Covid-19 Man­u­fac­tur­ing Roundup: Ther­mo Fish­er plant ramps up As­traZeneca vac­cine pro­duc­tion; No­vavax ex­pands Ko­re­an man­u­fac­tur­ing pact

Short­ly af­ter Ther­mo Fish­er’s $878.2 mil­lion buy­out of No­vasep’s vi­ral vec­tor man­u­fac­tur­ing busi­ness, it took over a plant in Bel­gium tasked with pro­duc­ing ade­n­ovirus vec­tors for As­traZeneca’s ver­sion of the Covid-19 shot.

That pro­duc­tion agree­ment was in­sti­gat­ed when No­vasep was still in charge, and the plant shoul­dered much of the blame for the oft-pub­li­cized slow­down of vac­cine out­put in re­cent weeks. Now that Ther­mo Fish­er has tak­en over, though, the plant has “dras­ti­cal­ly” ramped up its pro­duc­tion of late, Reuters re­port­ed Wednes­day. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER